Biomind Labs Inc.
BMNDF
$0.02
-$0.08-84.20%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.53% | -12.69% | -43.82% | -59.96% | -78.59% |
| Depreciation & Amortization | 0.00% | 33.33% | -4.35% | -66.33% | -76.68% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.72% | -40.83% | -59.20% | -71.74% | -79.97% |
| Operating Income | 10.72% | 40.83% | 59.20% | 71.74% | 79.97% |
| Income Before Tax | 94.28% | 85.07% | 78.16% | 51.50% | 64.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 94.28% | 85.07% | 78.16% | 51.50% | 64.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.28% | 85.07% | 78.16% | 51.50% | 64.65% |
| EBIT | 10.72% | 40.83% | 59.20% | 71.74% | 79.97% |
| EBITDA | 8.74% | 40.66% | 59.31% | 71.94% | 80.55% |
| EPS Basic | 94.34% | 84.92% | 77.99% | 52.06% | 64.78% |
| Normalized Basic EPS | 86.76% | 77.50% | 77.00% | 50.82% | 63.83% |
| EPS Diluted | 94.34% | 84.92% | 77.99% | 52.06% | 64.78% |
| Normalized Diluted EPS | 86.76% | 77.50% | 77.00% | 50.82% | 63.83% |
| Average Basic Shares Outstanding | 3.72% | 2.79% | 1.85% | 0.91% | 0.00% |
| Average Diluted Shares Outstanding | 3.72% | 2.79% | 1.85% | 0.91% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |